CMS Finalizes Rate Hike for BG Medicine's Galectin-3 Test | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that the Centers for Medicare and Medicaid Services have published the final determination of the 2014 Medicare national limitation amount for the company's galectin-3 test, arriving at a price of $30.01.

This is an increase over the test's 2013 national limitation of $17.80, and represents a win for BG Medicine, which had petitioned CMS for reconsideration of the 2013 determination.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.